BRAF and non-small cell lung carcinoma: Besides its role in tumorigenesis, the Hippo pathway plays a pivotal role in drug resistance of NSCLC via crosstalk with other well-known tumor-promoting factors such as EGFR, ALK, BRAF, KRAS, and ROS1 [91–98].